Reported 18 days ago
Jefferies analysts anticipate substantial gains for two small biotech stocks, Metagenomi (MGX) and Structure Therapeutics (GPCR), suggesting a potential increase of up to 1000% due to favorable market conditions following the recent elections. Both companies focus on innovative treatments in gene editing and chronic conditions, respectively, with promising clinical data supporting their growth prospects. MGX's price target indicates a potential gain of 1,035%, while GPCR projects a 165% increase, both classified as 'Strong Buy' by analysts.
Source: YAHOO